Cited by 157Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Open access

Ramjee, Vimal, Sperling, Laurence S., Jacobson, Terry A.·2011·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2011.05.009

Open this paper in CoChat — free account Open PDF

Abstract

With the emergence of new lipid risk markers and a growing cardiometabolic risk burden in the United States, there is a need to better integrate residual risk into cardiovascular disease (CVD) risk stratification. In anticipation of the Adult Treatment Panel IV (ATP IV) guidelines from the National Cholesterol Education Program (NCEP), there exists controversy regarding the comparative performance of the 2 foremost markers, apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C), as they relate to the current standard of risk assessment and treatment: low-density lipoprotein cholesterol (LDL-C). Although some emerging markers may demonstrate better performance compared with LDL-C, certain fundamental characteristics intrinsic to a beneficial biomarker must be met prior to routine use. Collectively, studies have found that non-HDL-C and apoB perform better than LDL-C in CVD risk prediction, both on- and off-treatment, as well as in subclinical CVD risk prediction. The performance of non-HDL-C compared with apoB, however, has been a point of ongoing debate. Although both offer the practical benefits of accuracy independent of triglyceride level and prandial state, non-HDL-C proves to be the better marker of choice at this time, given established cutpoints with safe and achievable goals, no additional cost, and quick time to result with an easy mathematical calculation. The purpose of this review is to assess the performance of these parameters in this context and to discuss the considerations of implementation into clinical practice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2011.05.009

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Executive Summary: Heart Disease and Stroke Statistics—2010 Update
WRITING GROUP MEMBERS, Lloyd‐Jones, D. M., Adams, R. J., Brown, T. M., Carnethon, M. R., Dai, S., SIMONE, G. D., Ferguson, T. B., Ford, E. S., Furie, K. L., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192666 · Cited by 1,360
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 765
Non–HDL Cholesterol, Apolipoproteins A-I and B 100 , Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Statistical Evaluation of Prognostic versus Diagnostic Models: Beyond the ROC Curve
Cook, N. R. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.096529 · Cited by 697
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R., OLSSON, A. G., Færgeman, O., KJEKSHUS, J. K., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyörälà, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 618
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 526
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.16 · Cited by 370
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Self-citation
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309
Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study
Freedman, D. S., Otvos, J. D., Jeyarajah, E. J., SHALAUROVA, I. Y., Cupples, L. A., Parise, H., D’Agostino, R. B., Wilson, P. W. F., & Schaefer, E. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.032763 · Cited by 304
Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes
Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J. P., Trevisan, M., & Grundy, S. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1916 · Cited by 237
The importance of non–HDL cholesterol reporting in lipid management
Blaha, M. J., Blumenthal, R. S., Brinton, E. A., & Jacobson, T. A. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.013 · Cited by 195
Self-citation
Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Que´bec cardiovascular study)
Lamarche, B., Després, J., Moorjani, S., Cantin, B., Dagenais, G. R., & Lupien, P.-J. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80760-7 · Cited by 170
Non–High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI)
Bittner, V., Hardison, R., Kelsey, S. F., Weiner, B. H., Jacobs, A. K., & Sopko, G. (2002) · Circulation · doi:10.1161/01.cir.0000038496.57570.06 · Cited by 168
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
Ballantyne, C. M., Andrews, T. C., Hsia, J. A., Kramer, J. H., & Shear, C. L. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01638-1 · Cited by 166
Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events
van Lennep, J. E. R., Westerveld, H. T., van Lennep, H. W. O. R., Zwinderman, A. H., Erkelens, D. W., & van der Wall, E. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2408 · Cited by 152
Serum Lipids and Incidence of Coronary Heart Disease
Frost, P. H., Davis, B. R., Burlando, A. J., Curb, J. D., Guthrie, G. P., Isaacsohn, J. L., Wassertheil-Smoller, S. W., Wilson, A. C., & Stamler, J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2381 · Cited by 147
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 139
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
Sniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116
Population frequency distribution of non–high-density lipoprotein cholesterol (third national health and nutrition examination survey [NHANES iii], 1988–1994)
Gardner, C. D., Winkleby, M. A., & Fortmann, S. P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00918-8 · Cited by 95
Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals
Orakzai, S. H., Nasir, K., Blaha, M. J., Blumenthal, R. S., & Raggi, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.014 · Cited by 91
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use
Mora, S. (2009) · Circulation · doi:10.1161/circulationaha.108.819359 · Cited by 89
Utility of Non–High-Density Lipoprotein Cholesterol Versus Other Lipoprotein Measures in Detecting Subclinical Atherosclerosis in Young Adults (The Bogalusa Heart Study)
Frontini, M., Srinivasan, S. R., Xu, J.-H., Tang, R., Bond, M. G., & Berenson, G. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.01.071 · Cited by 80
Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth: Apolipoprotein Concentrations Do Not Materially Improve Prediction of Arterial Lesions in PDAY Subjects
Rainwater, D. L., McMahan, C. A., Malcom, G. T., Scheer, W. D., Roheim, P. S., McGill, H. C., & Strong, J. P. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.753 · Cited by 62
Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B
Stein, E. A., Sniderman, A. D., & Laskarzewski, P. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.006 · Cited by 58
Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men
Simon, A. C., Chironi, G. N., Gariépy, J., Pino, M. D., & Levenson, J. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.017 · Cited by 49
A novel complex deletion–insertion mutation mediated by Alu repetitive elements leads to lipoprotein lipase deficiency
Okubo, M., Horinishi, A., Saito, M., Ebara, T., Endo, Y., Kaku, K., Murase, T., & Eto, M. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.06.018 · Cited by 43
Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
Hoenig, M. R. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.143 · Cited by 33
Non–High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic Target
Maki, K. C., Galant, R., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.009 · Cited by 28
Non-high-density lipoprotein cholesterol and cardiovascular disease
Bittner, V. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200308000-00005 · Cited by 20
Andrea del Sarto
Browning, R. (1855) · Oxford University Press eBooks · doi:10.1093/oseo/instance.00121904 · Cited by 19

Flagged first, then by citations

2 of the 57 references couldn’t be matched to a known paper.

Sorted by citations

Metabolic syndrome update
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Self-citation
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Self-citation
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications
Martin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428
Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders
Upadhyay, R. K. (2015) · Journal of Lipids · doi:10.1155/2015/971453 · Cited by 380

See all 157

Authors: Ramjee, V., Sperling, L. S., & Jacobson, T. A.
Affiliations: Emory University (US)
Corresponding author: Jacobson, Terry A.
ORCID: Ramjee, Vimal
Sperling, Laurence S.
Jacobson, Terry A.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2011-07
Volume: 58
Issue: 5
Pages: 457-463
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2011.05.009
OpenAlex: W1571892311
Cited by: 157
References: 57
Citations by year: 2026: 7 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 19 · 2014: 15 · 2013: 28 · 2012: 15
FWCI: 3.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 746 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: non-HDL cholesterol, apolipoprotein B, cardiovascular risk stratification, residual cardiovascular risk, LDL cholesterol
MeSH terms: Apolipoproteins B, Cardiovascular Diseases, Coronary Artery Disease, Humans, Lipoproteins, Biomarkers, Practice Guidelines as Topic, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks